PE20080262A1 - Anticuerpo humanizado contra interleuquina-18 - Google Patents

Anticuerpo humanizado contra interleuquina-18

Info

Publication number
PE20080262A1
PE20080262A1 PE2007000638A PE2007000638A PE20080262A1 PE 20080262 A1 PE20080262 A1 PE 20080262A1 PE 2007000638 A PE2007000638 A PE 2007000638A PE 2007000638 A PE2007000638 A PE 2007000638A PE 20080262 A1 PE20080262 A1 PE 20080262A1
Authority
PE
Peru
Prior art keywords
seq
interleuquin
humanized antibody
antibody against
sec
Prior art date
Application number
PE2007000638A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Volker Germaschewski
Paul Andrew Hamblin
Ian Kirby
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38476914&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080262(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0610438A external-priority patent/GB0610438D0/en
Priority claimed from GB0611046A external-priority patent/GB0611046D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20080262A1 publication Critical patent/PE20080262A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)

Abstract

SE REFIERE A UN ANTICUERPO HUMANIZADO CONTRA INTERLEUQUINA-18 QUE TIENE LAS SIGUIENTES CDR: CDRH1:SEC.ID.N:1; CDRH2:SEC.ID.N:2; CDRH3:SEC.ID.N:3; CDRL1:SEC.ID.N:4; CDRL2:SEC.ID.N:5; CDRL6:SEC.ID.N:6, EN LAS QUE EL RESTO DE LA POSICION 71 DE LA CADENA LIGERA ESTA SUSTITUIDO POR UN AMINOACIDO SELECCIONADO DE TIROSINA, ADEMAS DE TENER UNA AFINIDAD DE UNION (KD) DE 90 pM O SUPERIOR CON RESPECTO A IL-18 HUMANA CUANDO SE MIDE RESONANCIA DE PLASMON SUPERFICIAL (POR EJEMPLO BIACORE T100) A 37C. REFERIDA TAMBIEN A UNA COMPSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNITARIAS TALES COMO ESCLEROSIS MULTIPLE, ARTRITIS REUMATOIDE, DIBETES TIPO 1, ENFERMEDAD INFLAMATORIA DEL INTESTINO (EII) Y SORIASIS
PE2007000638A 2006-05-25 2007-05-23 Anticuerpo humanizado contra interleuquina-18 PE20080262A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0610438A GB0610438D0 (en) 2006-05-25 2006-05-25 Immunoglobulins
GB0611046A GB0611046D0 (en) 2006-06-05 2006-06-05 Immunoglobulins

Publications (1)

Publication Number Publication Date
PE20080262A1 true PE20080262A1 (es) 2008-04-30

Family

ID=38476914

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000638A PE20080262A1 (es) 2006-05-25 2007-05-23 Anticuerpo humanizado contra interleuquina-18

Country Status (22)

Country Link
US (5) US8133978B2 (es)
EP (1) EP2027157B1 (es)
JP (1) JP5420399B2 (es)
KR (1) KR101416078B1 (es)
AR (1) AR061115A1 (es)
AU (1) AU2007267213B2 (es)
BR (1) BRPI0711908B8 (es)
CA (1) CA2652733C (es)
CR (1) CR10468A (es)
EA (1) EA017303B1 (es)
ES (1) ES2514495T3 (es)
IL (1) IL194995A0 (es)
MA (1) MA30486B1 (es)
MX (1) MX2008014842A (es)
MY (1) MY157173A (es)
NO (1) NO341921B1 (es)
NZ (1) NZ572565A (es)
PE (1) PE20080262A1 (es)
SG (1) SG172625A1 (es)
TW (1) TWI422387B (es)
WO (1) WO2007137984A2 (es)
ZA (1) ZA200809662B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
KR101416078B1 (ko) 2006-05-25 2014-07-07 글락소 그룹 리미티드 변형된 인간화 항­인터루킨­１８ 항체
KR102467302B1 (ko) 2007-09-26 2022-11-14 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
EP3521311A1 (en) 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2010020593A1 (en) * 2008-08-18 2010-02-25 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
US8645083B2 (en) * 2008-08-27 2014-02-04 Hoffmann-La Roche Inc. Method to screen high affinity antibody
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
KR101484375B1 (ko) 2009-08-25 2015-01-19 에프. 호프만-라 로슈 아게 속도 인자
WO2011098424A2 (en) 2010-02-09 2011-08-18 Glaxo Group Limited Treatment of a metabolic disorder
CA2795734A1 (en) * 2010-04-07 2011-10-13 Abbvie Inc. Tnf-.alpha. binding proteins
ME03069B (me) * 2010-11-23 2019-01-20 Glaxo Group Ltd Antigen vezujući proteini za onkostatin m (osm)
CA2819356C (en) 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US20130149308A1 (en) * 2011-08-12 2013-06-13 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US10570199B2 (en) 2012-11-21 2020-02-25 Km Biologics Co., Ltd. Human antibody against IL-18
JP2016519145A (ja) * 2013-05-15 2016-06-30 メディミューン リミテッド 組換え産生ポリペプチドの精製
JP6442404B2 (ja) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
BR112017014067B1 (pt) 2015-02-27 2021-01-12 Chugai Seiyaku Kabushiki Kaisha usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
WO2017076805A1 (en) * 2015-11-02 2017-05-11 Glaxosmithkline Intellectual Property Development Limited Use of an inhibitor of il18 for treatment of acute kidney injury
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
EP3698808A4 (en) 2017-10-20 2021-07-14 Hyogo College Of Medicine MEDICAL COMPOSITION CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES FOR THE PREVENTION OF POSTOPERATIVE ADHESION
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
JPWO2023286694A1 (es) 2021-07-13 2023-01-19
WO2023056193A2 (en) * 2021-09-29 2023-04-06 Chimera Bioengineering, Inc. Il-18 variants and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
RU2139351C1 (ru) * 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
EP0528767B1 (en) 1991-08-21 2000-01-12 Novartis AG Antibody derivatives
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6048972A (en) * 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
EP0692536B1 (en) 1994-07-14 2000-11-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo IFN-Y production inducing protein and monoclonal antibody of the same
JP2952750B2 (ja) * 1995-02-23 1999-09-27 株式会社林原生物化学研究所 モノクローナル抗体
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
EP0971959B1 (en) * 1997-04-07 2005-12-28 Genentech, Inc. Humanized antibodies and methods for forming humanized antibodies
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
ME00546B (me) 2000-02-21 2011-10-10 Serono Lab Korišćenje inhibitora il-18
US20020025317A1 (en) 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
EP1326897A2 (en) * 2000-10-13 2003-07-16 Biogen, Inc. Humanized anti-lt-beta-r antibodies
WO2002032374A2 (en) 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
WO2002066063A1 (fr) 2001-02-23 2002-08-29 Nippon Organon K.K. Traitements de maladies osseuses metaboliques
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
UA78516C2 (en) 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
EP1621616A4 (en) 2003-04-30 2007-07-04 Japan Science & Tech Agency ANTIHUMAN INTERLEUKIN-18 HUMAN ANTIBODY, FRAGMENT THEREOF AND METHOD OF USING SAME
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
SG151292A1 (en) 2004-03-30 2009-04-30 Glaxo Group Ltd Immunoglobulins
GB0425556D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
JP2009531295A (ja) 2006-02-22 2009-09-03 ユニバーシティ オブ チューリッヒ 自己免疫疾患又は脱髄疾患を処置するための方法
KR101416078B1 (ko) 2006-05-25 2014-07-07 글락소 그룹 리미티드 변형된 인간화 항­인터루킨­１８ 항체
WO2010020593A1 (en) 2008-08-18 2010-02-25 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists

Also Published As

Publication number Publication date
US8133978B2 (en) 2012-03-13
US8637018B2 (en) 2014-01-28
MA30486B1 (fr) 2009-06-01
MX2008014842A (es) 2009-02-17
US9499617B2 (en) 2016-11-22
BRPI0711908A2 (pt) 2012-01-03
AU2007267213B2 (en) 2012-03-29
EA200802182A1 (ru) 2009-06-30
EP2027157B1 (en) 2014-08-06
ZA200809662B (en) 2014-05-28
NO20084650L (no) 2008-12-19
CR10468A (es) 2009-01-09
AR061115A1 (es) 2008-08-06
IL194995A0 (en) 2011-08-01
SG172625A1 (en) 2011-07-28
KR20090023625A (ko) 2009-03-05
US10703814B2 (en) 2020-07-07
JP2009537608A (ja) 2009-10-29
BRPI0711908B8 (pt) 2021-05-25
CA2652733C (en) 2016-06-21
EP2027157A2 (en) 2009-02-25
KR101416078B1 (ko) 2014-07-07
NZ572565A (en) 2011-04-29
CA2652733A1 (en) 2007-12-06
BRPI0711908B1 (pt) 2020-08-04
AU2007267213A1 (en) 2007-12-06
US20170029497A1 (en) 2017-02-02
JP5420399B2 (ja) 2014-02-19
ES2514495T3 (es) 2014-10-28
US20120100137A1 (en) 2012-04-26
TW200808350A (en) 2008-02-16
US20190031753A1 (en) 2019-01-31
WO2007137984A2 (en) 2007-12-06
EA017303B1 (ru) 2012-11-30
NO341921B1 (no) 2018-02-19
MY157173A (en) 2016-05-13
WO2007137984A3 (en) 2008-01-24
US20140105894A1 (en) 2014-04-17
US20070292432A1 (en) 2007-12-20
TWI422387B (zh) 2014-01-11

Similar Documents

Publication Publication Date Title
PE20080262A1 (es) Anticuerpo humanizado contra interleuquina-18
JP2020500538A5 (es)
AR081556A1 (es) Proteinas de union al antigeno humanizadas
PE20080181A1 (es) Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer
AR068723A1 (es) Proteina que se une a antigenos que se une a il-23 humana y sus usos
AR071891A1 (es) Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
HRP20170882T1 (hr) Humani antigen-vezujući proteini koji se vežu za beta-klotho, fgf receptore i njihove komplekse
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
PE20120429A1 (es) Proteinas de enlace de miostatina
JP2015508762A5 (es)
PE20070998A1 (es) Moleculas de anticuerpo que tienen especificidad para la il-6-humana
JP2012505912A5 (es)
RS52176B (en) HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
RS53157B (en) SCLEROSTINE ANTIBODIES
PE20140133A1 (es) Nuevas proteinas de union a antigenos
RS54846B1 (sr) Novo anti-dr5 antitelo
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
RS53685B1 (en) HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
PE20142041A1 (es) Anticuerpos anti-il-36r
PE20131334A1 (es) Anticuerpo igg1 humanizado
PE20120554A1 (es) Polipeptidos y metodo de tratamiento

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed